風濕性關節炎、支氣管氣喘、潰瘍性結腸炎、過敏性疾病。

成人:起始劑量為每日5~60ml,視疾病而定

兒童:起始劑量為0.14~2mg/kg/day,分成3~4次服用,視疾病而定

體液及鹽類滯留、鉀流失、高血壓、水腫、早產兒肥大性心肌病變、肌肉無力、骨質疏鬆症、長骨病理性骨折、類固醇性肌肉病變、肌腱破裂、脊椎壓迫性骨折。
腹脹、血清肝酶增加、胰臟炎、消化性潰瘍且可能穿孔與出血、潰瘍性食道炎。
面部紅斑、發汗增加、皮膚試驗抑制性反應、紫斑及瘀血、皮膚薄脆、蕁麻疹、痙攣、頭痛、通常停藥後會顱內壓增加及視乳頭水腫、精神紊亂、暈眩。
醣類耐受性降低、類庫興氏症(Cushingoid state)、多毛症(hirsutism)、糖尿病人的對於胰島素或口服降血糖藥的需求增加、潛伏性糖尿病的表現、月經不規則。續發性腎上腺皮質及腦下垂體的不反應性，特別是在創傷、手術及疾病時的壓力。抑制孩童的生長。
眼球凸出、青光眼、眼內壓增加、後囊下白內障(posterior subcapsular cataracts)。
食慾增加、身體不適、反胃、體重增加。

Absorption
Rapid and almost completely absorbed (oral, IV, IM). Slow, but completely absorbed (tebutate).

Distribution
Protein binding is high; crosses the placenta.

Metabolism
Primarily hepatic, also renal and tissue to mainly inactive metabolites.

Elimination
Renal (inactive metabolites). Plasma t ½ is 2.1 to 3.5 h; biologic t ½ is 18 to 36 h.

Onset
Slow, 1 to 2 days (tebutate).

Peak
1 to 2 h (oral); 1 h (IV, IM).

Duration
1.25 to 1.5 days (oral); up to 4 wk (IM). Duration of action for tebutate is 1 to 3 wk.

Anticholinesterases
May antagonize anticholinesterase effects in myasthenia gravis.

Barbiturates
May decrease pharmacologic effect of prednisolone.

Contraceptives (oral), estrogens, ketoconazole
May decrease clearance of prednisolone.

Hydantoins, rifampin
May increase clearance and decrease efficacy of prednisolone.

Salicylate
May reduce serum levels and efficacy of salicylates.

Troleandomycin
May increase prednisolone effects.

1.全身性黴菌感染。
2.對本藥主成份或其他成份過敏者。

1.治療時應盡量採用最少劑量，視症狀許可減低劑量或將停藥時，須緩慢進行不可突然停藥。
2.治療期間有任何壓力發生時，激素療法應重新開始。
3.如果治療期間超過6週，應該監控眼內壓。